Moderna takes swipe at Trump as it opens new UK factory: ‘A country that still believes in vaccination’
Modernna’s general manager, the US pharmaceutical firm Oxfordshire opened a new production base, while the UK greeted the UK as a “country that believes in vaccination”.
The interpretation was made on the basis of an increase in the conceptual attitudes of anti-vax under Trump.
US Health Secretary Robert F Kennedy JR was known for his vaccine-throat views. He made a series of false claims about the damage caused by vaccines and encouraged refuted theories that make vaccines may be due to autism.
Although Modernna’s plan to open the first MRNA production facility in the UK was present before the second presidential period of Mr. Trump, General Manager Stephane Bancel said that the company has opened the factory in a country that still believes in vaccination ”.
The publisher told the publisher that the British operation may “pay dividends, if he demanded anti -vaccine rhetoric effects in the USA.
Bancel added, “If there are fewer appetite to use vaccines by governments in the world, including the US, we can invest less vaccines,” Bancel added. “We must invest in a demand for our products.”
As a part of the 10 -year strategic partnership with the government, Moderna invests more than £ 1 billion in the UK research and development.
The company said that the Modernna Innovation and Technology Center (MITC) on the Harwell Science and Innovation Campus near Chilton was the first land facility to produce MRNA jabs in England.
The government said that the facility may have 100 million doses per year and that it may rise to a pandema to 250 million and will create about 150 talented businesses.
After shelving or pause the planned UK investments this year, it comes in the midst of a challenging investment view for the sector in the UK.
Industry bosses recently told MPS that a “difficult” environment and pricing pressure has made the Britain a less attractive investment environment than other countries, such as the United States.
Last week, the UK pharmaceutical giant Glaxosmithkline announced its plans to put about £ 22 billion in US research, development and production in the next five years.
US -based drug producer Merck said that the British operation was scrapped for a 1 billion pound site that will be opened in London in 2027 in King’s Cross. The bosses blamed the government for not making enough investment for drugs and did not invest enough to affect 125 jobs because they did little for drugs and did not invest enough.
Days later, Astrazeneca announced that it plans to invest £ 200 million in a Cambridge research site.
Health Secretary Wes Streeting, Oxfordshire’daki “new state -of -the -art facility” “our nation’s health, innovation and economy to increase the next important moment, he said.
“The government invests billions of investments in this vital sector and will allow us to benefit from innovative vaccine technology while shifting health services to prevent health services from treatment.”
Darius Hughes, General Manager of Modernna, said that the site will strengthen the country’s “pandemic preparation”.
